Zobrazeno 1 - 10
of 841
pro vyhledávání: '"Jeffrey, Schlom"'
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-32 (2024)
Abstract Longitudinal sampling of tumor tissue from patients with solid cancers, aside from melanoma and a few other cases, is often unfeasible, and thus may not capture the plasticity of interactions between the tumor and immune system under selecti
Externí odkaz:
https://doaj.org/article/9a7a67bd92584ad988f0fb41a0f405ba
Autor:
Meghali Goswami, Nicole J. Toney, Stephanie C. Pitts, Carolina Celades, Jeffrey Schlom, Renee N. Donahue
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 8, Pp n/a-n/a (2024)
Abstract Background With the rapid adoption of immunotherapy for the treatment of cancer comes the pressing need for readily accessible biomarkers to guide immunotherapeutic strategies and offer insights into outcomes with specific treatments. Regula
Externí odkaz:
https://doaj.org/article/22e0ac6c6b8546899281f75c8e16ba5f
Autor:
Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in c
Externí odkaz:
https://doaj.org/article/6ac20f46999d4c22ad7ae1d4db6d5b32
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-22 (2024)
Abstract The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. T
Externí odkaz:
https://doaj.org/article/21c56c76fb7044b9b27a608c5350302d
Autor:
Renee N Donahue, Jeffrey Schlom, James L Gulley, James W Hodge, Claudia Palena, Duane H Hamilton, Sofia R Gameiro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
The development of vaccines, especially RNA-based, directed against patient-specific tumor neoepitopes is an active and productive area of cancer immunotherapy. Promising clinical results in melanoma and other solid tumor types are emerging. As with
Externí odkaz:
https://doaj.org/article/a0dfb2ad06104e178521dabe0f22daa7
Autor:
Filipa Lynce, Candace Mainor, Renee N. Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J. Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher Gallagher, Rita Nanda, Deena Graham, Erica M. Stringer-Reasor, Neelima Denduluri, Julie Collins, Ami Chitalia, Shruti Tiwari, Raquel Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M. Tolaney, Sandra M. Swain, Paula Pohlmann, Heather A. Parsons, Claudine Isaacs
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/c4e454b0c3264101a45975daf5ec89e4
Autor:
Arun Rajan, Renee N Donahue, Jeffrey Schlom, James L Gulley, Elizabeth Lamping, Osama Rahma, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Yulia Vugmeyster, Yo-Ting Tsai, Shania Bailey, Wiem Lassoued, Richy Agajanian, Andrew Weisman, Rena Ito, Masashi Sato, Andreas Machl
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Bintrafusp alfa, a first-in-class bifunctional fusion protein targeting transforming growth factor-β (TGF-β) and programmed cell death ligand 1, has demonstrated encouraging efficacy as second-line treatment in patients with non-small ce
Externí odkaz:
https://doaj.org/article/299f4d847daa42ea885a8c75c936bce7
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-15 (2023)
Abstract Tumor biopsy is often not available or difficult to obtain in patients with solid tumors. Investigation of the peripheral immune system allows for in-depth and dynamic profiling of patient immune response prior to and over the course of trea
Externí odkaz:
https://doaj.org/article/986fed1c29b5482299fa91156091c655
Autor:
Paul L Chariou, Christine M Minnar, Mayank Tandon, Mary R Guest, Raj Chari, Jeffrey Schlom, Sofia R Gameiro
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0287733 (2024)
Immune checkpoint blockade (ICB) targeting the programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) fails to provide clinical benefit for most cancer patients due to primary or acquired resistance. Drivers of ICB resistance include tumor a
Externí odkaz:
https://doaj.org/article/b16a5fa1ff184a238cef603abf88e301
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
The clinical success of immune checkpoint inhibitors (ICIs) has demonstrated the promise and challenges of cancer immunotherapy. There is an unmet need to develop novel cancer therapies that can provide clinical benefit for most patients with solid m
Externí odkaz:
https://doaj.org/article/e8fbab143a674dc7a197a8a86991489d